What Happened to Paradigm Peptides? Timeline of the Federal Case and the 70-Month Sentence
Matthew J. Kawa, the owner of online supplier Paradigm Peptides, was sentenced in August 2026 to 70 months in federal prison after pleading guilty to selling unapproved, misbranded drugs to roughly 54,000 customers between 2019 and 2024. Federal testing found that six products sold as SARMs actually contained testosterone. His sister and employee, Jennifer L. Stechkober, received 16 months. Kawa forfeited $5 million in proceeds.
Blackwell BioLabs Research Team
Research Team
Paradigm Peptides case: key facts
| Fact | Detail |
|---|---|
| Company | Paradigm Peptides (online storefront, Grant Park, Illinois) |
| Owner | Matthew J. Kawa, 48 |
| Sentence | 70 months federal prison + 1 year supervised release |
| Co-defendant | Jennifer L. Stechkober, 32 (sister, key employee): 16 months |
| Customers affected | ~54,000, in all 50 U.S. states and 80+ countries |
| Sales period | 2019 to 2024 |
| Proceeds forfeited | ~$5 million money judgment |
| Restitution ordered | $78,317.52 (joint) |
| Adulteration finding | 6 products sold as SARMs contained actual testosterone |
| Charges | Introducing unapproved new drugs into interstate commerce with intent to defraud and mislead; illegal importation (Kawa) |
| Court | U.S. District Court, Northern District of Indiana, Judge Cristal Brisco |
| Sentencing | August 2026 |
For the roughly 54,000 customers who ordered from Paradigm between 2019 and 2024, this case is more than a news story. It is a case study in what happens when a supplier's claims about purity, origin, and testing turn out to be fiction, and it has become the defining event in research peptide sourcing this year. Here is the full timeline, drawn from the Department of Justice record and contemporaneous reporting.
Who was Paradigm Peptides?
Paradigm Peptides was an online storefront operated by Kawa out of Grant Park, Illinois, with his sister, Jennifer L. Stechkober of Michigan City, Indiana, working as a key employee. The company sold peptides, selective androgen receptor modulators (SARMs), human chorionic gonadotropin (HCG), and other compounds, marketed as research products.
According to the Department of Justice, the products were marketed as FDA-approved and domestically manufactured. Neither claim was true. Prosecutors established that the inventory was imported from China, India, and other countries, and sold without testing.
What is the timeline of the Paradigm Peptides case?
2019 to 2024: Paradigm Peptides sells to approximately 54,000 unique customers across all 50 states and more than 80 countries. Federal prosecutors later calculated that Kawa derived roughly $5 million in proceeds from the operation.
2020 and 2022: The FDA issues warning letters to the company. Sales continue. At sentencing, the judge would cite these ignored warnings as a central aggravating factor.
2024: Federal investigators test Paradigm's products. Among the findings: six products sold as testosterone-mimicking SARMs contained actual testosterone, a controlled anabolic steroid hormone, rather than the compounds on the label.
2025: Kawa pleads guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, and to illegally importing merchandise. Stechkober pleads guilty to the drug charge.
August 2026: Judge Cristal Brisco sentences Kawa to 70 months in prison followed by one year of supervised release, saying he left "an incredible trail of harm" after ignoring "numerous warnings" from regulators. Stechkober receives 16 months. Both are ordered to pay $78,317.52 in restitution, and Kawa faces an additional $5 million money judgment. At the hearing, Kawa told the court: "I'm deeply sorry I betrayed that trust."
What harm did Paradigm Peptides customers report?
Court records and victim statements describe customers who experienced severe acne, suppressed natural testosterone production requiring hormone replacement therapy, cardiac issues, and psychological effects including suicidal ideation.
One customer, a 32-year-old marketing consultant named Dan Murphy, described developing steroid-induced psychosis after using products he believed were SARMs but which contained testosterone. "I lost friends, family, colleagues, clients and almost lost my life," he said publicly after the sentencing.
This is the core of why the adulteration mattered so much: customers were not receiving a lower-quality version of what they ordered. In multiple cases they were receiving an entirely different substance, a Schedule III controlled hormone, with a pharmacological profile they had no reason to expect and no way to detect.
What was the owner of Paradigm Peptides convicted of?
It is worth being precise about the charges, because they define the legal reality of this industry. Kawa was not sentenced for selling peptides per se. He was sentenced for:
Fraud and misbranding. Marketing unapproved drugs as FDA-approved and as domestically manufactured when they were neither.
Selling unapproved new drugs into interstate commerce with intent to defraud. The "intent to defraud and mislead" element is what elevated this from a regulatory matter to a felony carrying serious prison time.
Illegal importation. Bringing the underlying material in from overseas suppliers in violation of customs law.
The lesson for anyone evaluating a supplier is that the sales page is a legal document of sorts. Claims about FDA status, country of origin, and testing are exactly the claims federal prosecutors scrutinized, and exactly the claims a careful buyer should scrutinize too.
What does the case mean for the research peptide market?
The Paradigm case landed in an industry that operates with minimal pre-market oversight. Research peptides are not FDA-approved products, and no legitimate supplier should claim otherwise. In that environment, the burden of verification shifts almost entirely to documentation: batch-specific certificates of analysis, independent third-party testing, published purity data, and transparent sourcing.
Enforcement in this space has been described as "a game of whack-a-mole," meaning the closure of one bad actor does not clean up the market. It simply redistributes customers, some of whom will land on suppliers with the same practices under a different name.
The practical takeaway from the Paradigm timeline is that every red flag was visible before the indictment: FDA-approval claims that could not have been true, "domestic" branding on imported goods, and an absence of verifiable independent testing. The customers who were harmed had no realistic way to catch the testosterone adulteration themselves, but the claims surrounding it were checkable from day one.
In follow-up pieces, we break down what the adulteration findings reveal about unverified sourcing and a step-by-step process for vetting any research peptide supplier before ordering.
Frequently asked questions
Why did the owner of Paradigm Peptides go to prison?
Matthew Kawa pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, and to illegal importation. Prosecutors showed Paradigm marketed untested imported compounds as FDA-approved and U.S.-made, and that six products sold as SARMs contained actual testosterone.How long is the Paradigm Peptides prison sentence?
Kawa was sentenced to 70 months (about 5 years 10 months) in federal prison plus one year of supervised release. Jennifer Stechkober, a key employee, received 16 months.Is Paradigm Peptides still in business?
No. The federal case ended the operation; Kawa forfeited approximately $5 million in proceeds and was sentenced in August 2026.Did Paradigm Peptides customers get compensation?
The court ordered $78,317.52 in restitution and entered a $5 million money judgment against Kawa. The DOJ press release is the authoritative source on the financial orders in the case.Were Paradigm Peptides products FDA-approved?
No. That was central to the fraud: the products were marketed as FDA-approved, but research peptides and SARMs sold in this market are not FDA-approved drugs.All products sold by Blackwell BioLabs are for research use only. Nothing in this article is medical advice or a recommendation for human use of any compound discussed.
Sources:
TOPICS
Ready to source research-grade peptides?
All compounds are third-party tested with batch-specific Certificates of Analysis. US-based fulfillment.